ArticleDermatology and therapy2026
Minimal Disease Activity as a Therapeutic Goal in Atopic Dermatitis: Predictive Factors of Sustainability in a Multicenter Cohort.
Article in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMinimal disease activity (MDA) is an emerging therapeutic goal in atopic dermatitis (AD), providing a multidimensional assessment of disease control.
methodsWe conducted a retrospective multicenter study of adults with moderate-to-severe AD receiving biologics or JAK inhibitors. MDA was defined as Eczema Area and Severity Index (EASI) ≤ 3 and Pruritus Numerical Rating Scale (NRS) ≤ 1. Univariate analyses were performed to identify baseline predictors of sustained MDA at week 52 among patients who had previously achieved MDA at week 16.
resultsAmong 197 patients with week 16 data, 107 (54.3%) achieved MDA. Of these, 59 had data at week 52, and 51 (86.4%) maintained MDA in a per-protocol analysis among patients with available follow-up. Sustained MDA was associated with the absence of hand involvement and fewer prior conventional treatments. No significant differences were found in gender, body mass index (BMI), baseline EASI score, or years of diagnostic delay. A younger age showed a trend toward a significant association with MDA loss. No statistically significant differences were found in the sustainability of MDA at week 52 between treatment groups (dupilumab, tralokinumab, and upadacitinib).
conclusionsSustained MDA among early responders is feasible in real-life AD practice. Baseline characteristics may help identify patients most likely to benefit from early targeted treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.